Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of ~~January 9,~~April 10, 2018, there were outstanding ~~10,789,544~~10,796,094 shares of Common Stock, $0.05 par value and 2,136,919 shares of Class B Common Stock, $0.05 par value, which are convertible into Common Stock of the registrant on a share for share basis.

	Three Months Ended						Six Months Ended						Three Months Ended						Nine Months Ended
	December 2, 2017			November 26, 2016			December 2, 2017			November 26, 2016			March 3, 2018			February 25, 2017			March 3, 2018			February 25, 2017
Statements of Comprehensive Income (Loss)
Net sales	$	39,082		$	33,827		$	76,077		$	67,200		$	41,645		$	32,313		$	117,722		$	99,513
Cost of sales		25,708			22,863			50,555			45,996			27,578			21,621			78,133			67,617
Gross profit		13,374			10,964			25,522			21,204			14,067			10,692			39,589			31,896
Selling, general and administrative expenses		12,602			13,368			24,926			25,695			13,097			12,002			38,023			37,697
Gain on disposal of assets		—			—			(191	)		—
Loss (gain) on disposal of assets														3			—			(188	)		—
Operating income (loss)		772			(2,404	)		787			(4,491	)		967			(1,310	)		1,754			(5,801	)
Other (income) expense:
Investment/interest income		(36	)		(51	)		(170	)		(62	)		(208	)		(67	)		(378	)		(129	)
Foreign exchange loss (gain)		115			(181	)		316			97
Foreign exchange loss														159			214			475			311
Other, net		(11	)		17			(15	)		16			1			(16	)		(14	)		—
Total other expense (income)		68			(215	)		131			51
Total other (income) expense														(48	)		131			83			182
Income (loss) from continuing operations before income taxes		704			(2,189	)		656			(4,542	)		1,015			(1,441	)		1,671			(5,983	)
Income tax provision		532			333			596			830
Income tax provision (benefit)														488			(10	)		1,084			820
Income (loss) from continuing operations		172			(2,522	)		60			(5,372	)		527			(1,431	)		587			(6,803	)
Income from discontinued operations		1,496			—			1,496			—			—			—			1,496			—
Net income (loss)		1,668			(2,522	)		1,556			(5,372	)		527			(1,431	)		2,083			(6,803	)
Foreign currency translation gain (loss), net of tax		230			(2,623	)		2,351			(2,244	)		1,646			508			3,997			(1,736	)
Fair value adjustments on investments gain		48			6			34			13
Fair value adjustments on investments (loss) gain														(164	)		27			(130	)		40
Comprehensive income (loss)	$	1,946		$	(5,139	)	$	3,941		$	(7,603	)	$	2,009		$	(896	)	$	5,950		$	(8,499	)
Net income (loss) per Common share - Basic:
Net income (loss) per Common share - Basic:
Income (loss) from continuing operations	$	0.01		$	(0.20	)	$	—		$	(0.43	)	$	0.04		$	(0.11	)	$	0.05		$	(0.54	)
Income from discontinued operations		0.12			—			0.12			—			—			—			0.12			—
Total net income (loss) per Common share - Basic	$	0.13		$	(0.20	)	$	0.12		$	(0.43	)	$	0.04		$	(0.11	)	$	0.17		$	(0.54	)
Net income (loss) per Class B common share - Basic:
Net income (loss) per Class B common share - Basic:
Income (loss) from continuing operations	$	0.01		$	(0.18	)	$	—		$	(0.38	)	$	0.04		$	(0.10	)	$	0.04		$	(0.48	)
Income from discontinued operations		0.11			—			0.11			—			—			—			0.11			—
Total net income (loss) per Class B common share - Basic	$	0.12		$	(0.18	)	$	0.11		$	(0.38	)	$	0.04		$	(0.10	)	$	0.15		$	(0.48	)
Net income (loss) per Common share - Diluted:
Net income (loss) per Common share - Diluted:
Income (loss) from continuing operations	$	0.01		$	(0.20	)	$	—		$	(0.43	)	$	0.04		$	(0.11	)	$	0.05		$	(0.54	)
Income from discontinued operations		0.12			—			0.12			—			—			—			0.12			—
Total net income (loss) per Common share – Diluted	$	0.13		$	(0.20	)	$	0.12		$	(0.43	)	$	0.04		$	(0.11	)	$	0.17		$	(0.54	)
Net income (loss) per Class B common share - Diluted:
Net income (loss) per Class B common share - Diluted:
Income (loss) from continuing operations	$	0.01		$	(0.18	)	$	—		$	(0.38	)	$	0.04		$	(0.10	)	$	0.04		$	(0.48	)
Income from discontinued operations		0.11			—			0.11			—			—			—			0.11			—
Total net income (loss) per Class B common share - Diluted	$	0.12		$	(0.18	)	$	0.11		$	(0.38	)
Total net income (loss) per Class B common share – Diluted													$	0.04		$	(0.10	)	$	0.15		$	(0.48	)
Weighted average number of shares:
Common shares – Basic		10,755			10,703			10,734			10,703			10,792			10,706			10,753			10,704
Class B common shares – Basic		2,137			2,141			2,137			2,141			2,137			2,141			2,137			2,141
Common shares – Diluted		10,789			10,703			10,764			10,703			10,872			10,706			10,793			10,704
Class B common shares – Diluted		2,137			2,141			2,137			2,141			2,137			2,141			2,137			2,141
Dividends per common share	$	0.060		$	0.060		$	0.120		$	0.120		$	0.060		$	0.060		$	0.180		$	0.180
Dividends per Class B common share	$	0.054		$	0.054		$	0.108		$	0.108		$	0.054		$	0.054		$	0.162		$	0.162

	Three Months Ended						Six Months Ended						Three Months Ended						Nine Months Ended
	December 2, 2017			November 26, 2016			December 2, 2017			November 26, 2016			March 3, 2018			February 25, 2017			March 3, 2018			February 25, 2017
Operating activities:
Net income (loss)	$	1,668		$	(2,522	)	$	1,556		$	(5,372	)	$	527		$	(1,431	)	$	2,083		$	(6,803	)
Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities:
Depreciation and amortization		735			602			1,467			1,317			752			703			2,219			2,020
Inventory provisions		125			66			287			109			183			189			470			298
Loss (gain) on sale of investments		1			8			(24	)		6
Gain on disposal of assets		—			—			(191	)		—
Gain on sale of investments														(159	)		(8	)		(183	)		(2	)
Loss (gain) on disposal of assets														3			—			(188	)		—
Share-based compensation expense		208			176			309			279			116			75			425			354
Deferred income taxes		66			(151	)		62			(309	)		124			121			186			(188	)
Change in assets and liabilities:
Accounts receivable		(1,735	)		379			312			3,934			(551	)		(717	)		(239	)		3,217
Income tax receivable		—			8			—			(5	)		—			—			—			(5	)
Inventories		(2,021	)		1,115			(4,634	)		1,483			(598	)		117			(5,232	)		1,600
Prepaid expenses and other assets		(357	)		(1,082	)		(615	)		(1,041	)		43			80			(572	)		(961	)
Accounts payable		1,757			(883	)		(998	)		(3,221	)		552			849			(446	)		(2,372	)
Accrued liabilities		(517	)		2,006			209			862			1,116			(1,118	)		1,325			(256	)
Other		264			13			(3	)		18			(137	)		(125	)		(140	)		(107	)
Net cash provided by (used in) operating activities		194			(265	)		(2,263	)		(1,940	)		1,971			(1,265	)		(292	)		(3,205	)
Investing activities:
Capital expenditures		(1,720	)		(1,235	)		(2,735	)		(3,299	)		(1,461	)		(764	)		(4,196	)		(4,063	)
Proceeds from sale of assets		—			—			276			—			—			—			276			—
Proceeds from maturity of investments		4,177			2,117			8,177			3,582			3,943			—			12,120			3,582
Purchases of investments		(3,943	)		(2,136	)		(3,943	)		(2,136	)		—			—			(3,943	)		(2,136	)
Proceeds from sales of available-for-sale securities		114			59			265			147			648			78			913			225
Purchases of available-for-sale securities		(114	)		(59	)		(265	)		(147	)		—			(78	)		(265	)		(225	)
Other		(2	)		(3	)		(5	)		(6	)		(2	)		(3	)		(7	)		(9	)
Net cash (used in) provided by investing activities		(1,488	)		(1,257	)		1,770			(1,859	)
Net cash provided by (used in) investing activities														3,128			(767	)		4,898			(2,626	)
Financing activities:
Proceeds from issuance of common stock														44			30			44			30
Cash dividends paid		(763	)		(757	)		(1,521	)		(1,515	)		(763	)		(758	)		(2,284	)		(2,273	)
Net cash used in financing activities		(763	)		(757	)		(1,521	)		(1,515	)		(719	)		(728	)		(2,240	)		(2,243	)
Effect of exchange rate changes on cash and cash equivalents		81			(1,098	)		1,140			(1,029	)		1,049			35			2,189			(994	)
Decrease in cash and cash equivalents		(1,976	)		(3,377	)		(874	)		(6,343	)
Increase (decrease) in cash and cash equivalents														5,429			(2,725	)		4,555			(9,068	)
Cash and cash equivalents at beginning of period		56,429			57,488			55,327			60,454			54,453			54,111			55,327			60,454
Cash and cash equivalents at end of period	$	54,453		$	54,111		$	54,453		$	54,111		$	59,882		$	51,386		$	59,882		$	51,386

	Common		Class B Common		Par Value		Additional Paid In Capital		Common Stock in Treasury		Retained Earnings			Accumulated Other Comprehensive Income		Total			Common		Class B Common		Par Value		Additional Paid In Capital		Common Stock in Treasury		Retained Earnings			Accumulated Other Comprehensive Income			Total
Balance May 27, 2017:		10,712		2,137	$	642	$	59,436	$	—	$	69,333		$	2,916	$	132,327			10,712		2,137	$	642	$	59,436	$	—	$	69,333		$	2,916		$	132,327
Comprehensive income
Net income		—		—		—		—		—		1,556			—		1,556			—		—		—		—		—		2,083			—			2,083
Foreign currency translation		—		—		—		—		—		—			2,351		2,351			—		—		—		—		—		—			3,997			3,997
Fair value adjustments on investments		—		—		—		—		—		—			34		34			—		—		—		—		—		—			(130	)		(130	)
Share-based compensation:
Restricted stock		78		—		—		23		—		—			—		23			78		—		—		57		—		—			—			57
Stock options		—		—		—		286		—		—			—		286			—		—		—		368		—		—			—			368
Common stock:
Options exercised																				6		—		5		39		—		—			—			44
Dividends paid to:
Common ($0.12 per share)		—		—		—		—		—		(1,290	)		—		(1,290	)
Class B ($0.108 per share)		—		—		—		—		—		(231	)		—		(231	)
Balance December 2, 2017:		10,790		2,137	$	642	$	59,745	$	—	$	69,368		$	5,301	$	135,056
Common ($0.18 per share)																				—		—		—		—		—		(1,938	)		—			(1,938	)
Class B ($0.162 per share)																				—		—		—		—		—		(346	)		—			(346	)
Balance March 3, 2018:																				10,796		2,137	$	647	$	59,900	$	—	$	69,132		$	6,783		$	136,462

Richardson Electronics, Ltd. is a leading global provider of engineered solutions, power grid and microwave tubes and related consumables; power conversion and RF and microwave components; high value flat panel detector solutions, replacement parts, tubes and service training for diagnostic imaging equipment; and customized display solutions. We serve customers in the alternative energy, healthcare, aviation, broadcast, communications, industrial, marine, medical, military, scientific and semiconductor markets. The Company’s strategy is to provide specialized technical expertise and “engineered solutions” based on our core engineering and manufacturing capabilities. The Company provides solutions and adds value through design-in support, systems integration, prototype design and manufacturing, testing, logistics, and aftermarket technical service and repair through its global infrastructure.

Our products include electron tubes and related components, microwave generators, subsystems used in semiconductor manufacturing, and visual technology solutions. These products are used to control, switch or amplify electrical power signals, or are used as display devices in a variety of industrial, commercial, medical, and communication applications.

Power and Microwave Technologies Group (“PMT”) combines our core engineered solutions, power grid and microwave tube business with new RF and power technologies. As a manufacturer and authorized distributor, PMT’s strategy is to provide specialized technical expertise and engineered solutions based on our core engineering and manufacturing capabilities. We provide solutions and add value through design-in support, systems integration, prototype design and manufacturing, testing, logistics, and aftermarket technical service and repair—all through our existing global infrastructure. PMT’s focus is on products for power, RF and microwave applications for customers in alternative energy, aviation, broadcast, communications, industrial, marine, medical, military, scientific, and semiconductor markets. PMT focuses on various applications including broadcast transmission, CO2 laser cutting, diagnostic imaging, dielectric and induction heating, high energy transfer, high voltage switching, plasma, power conversion, radar, and radiation oncology. PMT also offers its customers technical services for both microwave and industrial equipment.

Canvys provides customized display solutions serving the corporate enterprise, financial, healthcare, industrial, and medical original equipment manufacturers (“OEM”) markets.

Healthcare manufactures, refurbishes and distributes high value replacement parts for the healthcare market including hospitals, medical centers, asset management companies, independent service organizations, and multi-vendor service providers. Products include Diagnostic Imaging replacement parts for CT and MRI systems; replacement CT and MRI tubes; CT service training; MRI coils, cold heads, and RF amplifiers; hydrogen thyratrons, klystrons, magnetrons; flat panel detector upgrades; and additional replacement solutions currently under development for the diagnostic imaging service market. Through a combination of newly developed products and partnerships, service offerings, and training programs, we believe we can help our customers improve efficiency and deliver better clinical outcomes while lowering the cost of healthcare delivery.

We currently have operations in the following major geographic regions: North America, Asia/Pacific, Europe and Latin America.

The accompanying unaudited consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and notes required by GAAP for complete financial statements.

Our fiscal quarter ends on the Saturday nearest the end of the quarter-ending month. The ~~second~~third quarter of fiscal 2018 and fiscal 2017 both contained 13 weeks. The first ~~six~~nine months of fiscal 2018 and fiscal 2017 contained 2740 and 2639 weeks, respectively.

In the opinion of management, all adjustments, which are of a normal and recurring nature, necessary for a fair presentation of the results of interim periods have been made. All inter-company transactions and balances have been eliminated. The unaudited consolidated financial statements presented herein include the accounts of our wholly owned subsidiaries. Certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The results of our operations for the three and ~~six~~nine months ended ~~December 2, 2017,~~March 3, 2018, are not necessarily indicative of the results that may be expected for the fiscal year ending June 2, 2018.

The financial information contained in this report should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended May 27, 2017, that we filed on July 31, 2017.

Inventories, net: Our consolidated inventories are stated at the lower of cost ~~or market,~~and net realizable value, generally using a weighted-average cost method. Our net inventories include approximately ~~$39.9~~$40.9 million of finished goods, ~~$5.8~~$5.7 million of raw materials and ~~$2.4~~$2.5 million of work-in-progress as of ~~December 2, 2017,~~March 3, 2018, as compared to approximately $36.0 million of finished goods, $5.3 million of raw materials and $1.4 million of work-in-progress as of May 27, 2017.

At this time, we do not anticipate any material risks or uncertainties related to possible future inventory write-downs. Provisions for obsolete or slow moving inventories are recorded based upon regular analysis of stock rotation privileges, obsolescence, the exiting of certain markets and assumptions about future demand and market conditions. If future demand changes in the industry, or market conditions differ from management’s estimates, additional provisions may be necessary. Inventory reserves were approximately ~~$3.6~~$3.7 million as of ~~December 2, 2017~~March 3, 2018 and $3.5 million as of May 27, 2017.

Revenue Recognition: Our product sales are recognized as revenue upon shipment, when title passes to the customer, when delivery has occurred or services have been rendered and when collectability is reasonably assured. We also record estimated discounts and returns based on our historical experience. Our products are often manufactured to meet the specific design needs of our customers’ applications. Our engineers work closely with customers to ensure that our products will meet their needs. Our customers are under no obligation to compensate us for designing the products we sell.

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers, which amends guidance for revenue recognition. ASU 2014-09 is principles based guidance that can be applied to all contracts with customers, enhancing comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets. The core principle of the guidance is that entities should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The guidance details the steps entities should apply to achieve the core principle. In August 2015, the FASB issued an amendment to defer the effective date for all entities by one year. For public entities, ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted as of annual reporting periods beginning after December 15, 2016. Companies have the option of using either a full or modified retrospective approach in applying this standard. During fiscal 2016 and 2017, the FASB issued four additional updates which further clarify the guidance provided in ASU 2014-09.

We are evaluating the impact of the new standard on our financial statements using a three-phase approach (assessment, conversion and implementation). We continue to work through our assessment phase and further evaluation is needed in order to determine whether or not the new revenue recognition standard will have a material impact on our financial statements and related disclosures upon adoption. We have undertaken a detailed analysis of our various contracts with customers and revenue streams. The Company has engaged a third party to assist in evaluating the impact of this new standard on its consolidated financial statements and related disclosures. We will complete the conversion and implementation phases by the end of fiscal year 2018 in conjunction with future interpretative guidance.

Loss Contingencies: We accrue a liability for loss contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. If we determine that there is at least a reasonable possibility that a loss may have been incurred, we will include a disclosure describing the contingency.

Goodwill and Intangible Assets: We test goodwill for impairment annually and whenever events or circumstances indicate an impairment may have occurred, such as a significant adverse change in the business climate, loss of key personnel or a decision to sell or dispose of a reporting unit.

During the fourth quarter of each fiscal year, our goodwill balances are reviewed for impairment using the first day of our fourth quarter as the measurement date. If after reviewing the totality of events or circumstances, we determine that it is not likely that the fair value of a reporting unit exceeds its carrying amount, then we test for impairment through the application of a fair value based test. We estimate the fair value of each of our reporting units based on projected future operating results, market approach, and discounted cash flows.

Intangible assets are initially recorded at their fair market values determined on quoted market prices in active markets, if available, or recognized valuation models. Intangible assets that have finite useful lives are amortized over their useful lives either on a straight-line basis or over their projected future cash flows and are tested for impairment when events or changes in circumstances occur that indicate possible impairment.

Income Taxes: We recognize deferred tax assets and liabilities based on the differences between financial statement carrying amounts and the tax bases of assets and liabilities. We regularly review our deferred tax assets for recoverability and determine the need for a valuation allowance based on a number of factors, including both positive and negative evidence. These factors include historical taxable income or loss, projected future taxable income or loss, the expected timing of the reversals of existing temporary differences and the implementation of tax planning strategies. In circumstances where we, or any of our affiliates, have incurred three years of cumulative losses which constitute significant negative evidence, positive evidence of equal or greater significance is needed to overcome the negative evidence before a tax benefit is recognized for deductible temporary differences and loss carryforwards.

In March 2016, the FASB issued ASU No. 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”, a new accounting standard update intended to simplify several aspects of the accounting for share-based payment transactions including: income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. Specifically, the update requires that excess tax benefits and tax deficiencies (the difference between the deduction for tax purposes and the compensation cost recognized for financial reporting purposes) be recognized as income tax expense or benefit in the consolidated statements of comprehensive income (loss), introducing a new element of volatility to the provision for income taxes. This update is effective for fiscal years beginning after December 15, 2016. Early adoption is permitted. The Company adopted the ASU on May 28, 2017. Effective with the adoption of the ASU all share-based awards continue to be accounted for as equity awards, excess tax benefits recognized on stock-based compensation expense are reflected in the consolidated statements of comprehensive income (loss) as a component of the provision for income taxes on a prospective basis, excess tax benefits recognized on stock-based compensation expense are classified as an operating activity in the consolidated statements of cash flows on a prospective basis and the Company has elected to continue to estimate expected forfeitures over the course of a vesting period. The adoption of the ASU had no impact on the retained earnings, other components of equity or net assets as of the beginning of the period of adoption.

Accrued Liabilities: Accrued liabilities consist of the following (in thousands):

	December 2, 2017		May 27, 2017		March 3, 2018		May 27, 2017
Compensation and payroll taxes	$	3,006	$	3,250	$	3,328	$	3,250
Accrued severance (1)		410		706		410		706
Professional fees		603		535		642		535
Deferred revenue		1,716		1,460		2,051		1,460
Other accrued expenses		2,910		2,360		3,436		2,360
Accrued Liabilities	$	8,645	$	8,311	$	9,867	$	8,311

(1) In the second quarter of fiscal year 2017, the Company executed a reduction in headcount to streamline operations and reduce costs and recorded $1.3 million of expense included in selling, general and administrative expenses for employee termination costs payable to terminated employees with employment and/or separation agreements with the Company. The changes in the severance accrual for the first ~~six~~nine months of fiscal year 2018 included payments of $0.3 million.

The carrying value of goodwill was $6.3 million as of ~~December 2, 2017~~March 3, 2018 and May 27, 2017.

Goodwill is initially recorded based on the premium paid for acquisitions and is subsequently tested for impairment, using the first day of our fourth quarter as the measurement date. We test goodwill for impairment annually and whenever events or circumstances indicates an impairment may have occurred, such as a significant adverse change in the business climate, loss of key personnel or a decision to sell or dispose of a reporting unit. The goodwill balance in its entirety relates to our IMES reporting unit which is included in our Healthcare segment.

Our intangible assets represent the fair value for trade name, customer relationships, non-compete agreements and technology acquired in connection with our acquisitions. Intangible assets subject to amortization are as follows (in thousands):

	December 2, 2017		May 27, 2017		March 3, 2018		May 27, 2017
Gross Amounts:
Trade Name	$	659	$	659	$	659	$	659
Customer Relationships⁽¹⁾		3,411		3,397		3,417		3,397
Non-compete Agreements		177		177		177		177
Technology		230		230		230		230
Total Gross Amounts	$	4,477	$	4,463	$	4,483	$	4,463
Accumulated Amortization:
Trade Name	$	546	$	441	$	598	$	441
Customer Relationships		536		446		582		446
Non-compete Agreements		100		84		107		84
Technology		64		51		71		51
Total Accumulated Amortization	$	1,246	$	1,022	$	1,358	$	1,022

Net Intangibles	$	3,231	$	3,441	$	3,125	$	3,441

The amortization expense associated with the intangible assets subject to amortization for the next five years is presented in the following table (in thousands):

Fiscal Year	Amortization Expense		Amortization Expense
Remaining 2018	$	216	$	108
2019		245		245
2020		257		258
2021		245		246
2022		253		253
Thereafter		2,015		2,015
Total amortization expense	$	3,231	$	3,125

The weighted average number of years of amortization expense remaining is ~~16.1~~15.9 years.

As of ~~December 2, 2017,~~March 3, 2018, we had approximately ~~$4.1~~$0.2 million invested in time deposits and certificates of deposit (“CD”) which mature in less than twelve months. The fair value of these investments is equal to the face value of each time deposit and CD.

As of May 27, 2017, we had invested in time deposits and certificates of deposit in the amount of $8.2 million. Of this, $6.4 million mature in less than twelve months and $1.8 million mature in greater than twelve months. The fair value of these investments is the face value of each time deposit and CD.

We ~~also had~~liquidated our investments in equity securities ~~all~~in the third quarter of ~~which are~~fiscal 2018. Proceeds from the liquidation were $0.9 million with gross realized gains of $0.2 million for the nine months ended March 3, 2018. Prior to the liquidation of our investment in equity securities, our investments in equity securities were classified as available-for-sale and ~~are~~were carried at their fair value based on quoted market prices. Our investments, which ~~are~~were included in non-current assets, had a carrying amount of ~~$0.7 million and~~ $0.6 million as of ~~December 2, 2017 and as of~~ May 27, ~~2017, respectively.~~2017. Proceeds from the sale of securities were $0.1 million during the ~~second quarter of fiscal 2018 and during the second~~third quarter of fiscal 2017. WePrior to liquidating the equity securities, we reinvested proceeds from the sale of securities, and the cost of the equity securities sold was based on a specific identification method. Gross realized gains on those sales were less than $0.1 million during the ~~second quarter of fiscal 2018 and during the second~~third quarter of fiscal 2017. Net unrealized holding gains of less than $0.1 million during the ~~second quarter of fiscal 2018 and during the second~~third quarter of fiscal 2017 ~~have been~~were included in accumulated other comprehensive income (loss).

We offer warranties for the limited number of specific products we manufacture. We also provide extended warranties for some products we sell that lengthen the period of coverage specified in the manufacturer’s original warranty. Our warranty terms generally range from one to three years.

We estimate the cost to perform under the warranty obligation and recognize this estimated cost at the time of the related product sale. We record expense related to our warranty obligations as cost of sales in our consolidated statements of comprehensive income (loss). Each quarter, we assess actual warranty costs incurred on a product-by-product basis and compare the warranty costs to our estimated warranty obligation. With respect to new products, estimates are based generally on knowledge of the products, the extended warranty period and warranty experience.

Warranty reserves are established for costs that are expected to be incurred after the sale and delivery of products under warranty. Warranty reserves are included in accrued liabilities on our consolidated balance sheets. The warranty reserves are determined based on known product failures, historical experience and other available evidence. Warranty reserves were approximately $0.1 million as of ~~December 2, 2017~~March 3, 2018 and ~~as of~~ May 27, 2017.

We lease certain warehouse and office facilities and office equipment under non-cancelable operating leases. Rent expense was ~~$0.9~~$1.3 million during the first ~~six~~nine months of fiscal 2018 and ~~$1.0~~$1.5 million during the first ~~six~~nine months of fiscal 2017. Our future lease commitments for minimum rentals, including common area maintenance charges and property taxes during the next five years are as follows (in thousands):

Fiscal Year	Payments		Payments
Remaining 2018	$	887	$	454
2019		1,613		1,622
2020		1,162		1,143
2021		827		802
2022		174		144
Thereafter		195		97

We recorded an income tax provision from continuing operations of ~~$0.6~~$1.1 million and $0.8 million for the first ~~six~~nine months of fiscal 2018 and the first nine months of fiscal 2017, respectively. The effective income tax rate from continuing operations during the first ~~six~~nine months of fiscal 2018 was a tax provision of ~~90.9%~~65.0%, as compared to a tax provision of ~~(18.3%~~(13.7%) during the first ~~six~~nine months of fiscal 2017. The difference in rate during the first ~~six~~nine months of fiscal 2018, as compared to the first ~~six~~nine months of fiscal 2017, reflects the change in the overall loss realized through the ~~second~~third quarter in each respective period, changes in our geographical distribution of income (loss), the recording of provision to return true-ups of various foreign jurisdictions, the accrual of an uncertain tax position with respect to ~~the ongoing~~a German audit and our positions with respect to permanent reinvestment of foreign earnings under ASC 740-30, Income Taxes - Other Considerations or Special Areas (“ASC 740-30”). The ~~90.9%~~65.0% effective income tax rate differs from the federal statutory rate of ~~34.0%~~29.2% as a result of our geographical distribution of income (loss), the recording of a valuation allowance against the increase in our U.S. state and federal net deferred tax assets, ~~and~~ recognition of an uncertain tax position and preliminary tax assessments with respect to the income tax audit in Germany.

On December 22, 2017, the U.S. government enacted new tax legislation, Tax Cuts and Jobs Act (the “Act”). The primary provisions of the Act expected to impact the Company in fiscal 2018 are a reduction to the U.S. corporate income tax rate from 35% to 21% and a transition from a worldwide corporate tax system to a territorial tax system. The reduction in the corporate income tax rate requires the Company to remeasure its net deferred tax assets to the new corporate tax rate and the transition to a territorial tax system requires payment of a one-time tax on deemed repatriation of undistributed and previously untaxed non-U.S. earnings. Primarily as a result of those provisions of the Act, the Company recorded a deferred remeasurement impact of approximately $1.6 million, which was fully offset by the valuation allowance movement. Additionally, the estimated deemed earnings repatriation tax, net of available foreign tax credits brought back as part of the deemed repatriation, was $3.5 million. The Company does not anticipate any cash tax payments due to the foreign tax credit carryforwards available to fully offset the provisional deemed repatriation tax.

The 21% corporate income tax rate was effective January 1, 2018. Based on the Company’s June 2, 2018 fiscal year end, the U.S. statutory income tax rate for fiscal 2018 will be approximately 29.2%.

The tax impact recorded for the Act during the third quarter of fiscal 2018 was provisional as outlined below and may change. The Company completed a preliminary assessment of earnings that could be repatriated based on reinvestment needs of non-U.S. operations and earnings available for repatriation. The estimated withholding tax that would be incurred from the repatriation of those earnings is included in the third quarter of fiscal 2018 provisional income tax expense. The Company continues to analyze the provisions of the Act addressing the net deferred tax asset remeasurement and its calculations, the deemed earnings repatriation, including the determination of undistributed non-U.S. earnings, and evaluate potential Company actions, including repatriating additional non-U.S. earnings and actions that could affect the Company’s fiscal year ended 2018 U.S. taxable income. In addition, the Company continues to monitor potential legislative action and regulatory interpretations of the Act.

Based on the effective date of certain provisions, the Company will be subject to additional requirements of the Act beginning in fiscal 2019. Those provisions include a tax on global intangible low-taxed income (GILTI), a tax determined by base erosion tax benefits (BEAT) from certain payments between a U.S. corporation and foreign subsidiaries, a limitation of certain executive compensation, a deduction for foreign derived intangible income (FDII) and interest expense limitations. The Company has not completed its analysis of those provisions and the estimated impact. The Company also has not determined its accounting policy to treat the taxes due on GILTI as a period cost or include in the determination of deferred taxes.

In December 2017, the SEC issued Staff Accounting Bulletin No. 118 that allows for a measurement period up to one year after the enactment date of the Act to complete the accounting requirements. The Company will complete the adjustments related to the Act within the allowed period.

We have historically determined that undistributed earnings of our foreign subsidiaries, to the extent of cash available, will be repatriated to the U.S. Due to the deemed earnings repatriation tax, the outside basis difference for which the historic balance has primarily related has been reduced. The deferred tax liability on the outside basis difference is now primarily withholding tax. Accordingly, we have reduced the deferred tax liability from $5.7 million as of the second quarter of fiscal 2018 to $0.2 million as of the third quarter of fiscal 2018 on foreign earnings of $47.2 million.

In the normal course of business, we are subject to examination by taxing authorities throughout the world. Generally, years prior to fiscal 2007 are closed for examination under the statute of limitation for U.S. federal, U.S. state and local or non-U.S. tax jurisdictions. We are currently under examination in Thailand (fiscal 2008 through 2011). We are also under examination in the state of Illinois for fiscal years 2014 and 2015. Our primary foreign tax jurisdictions are Germany and the Netherlands. During the second quarter of fiscal 2018, the examination in Germany of years 2012-2014 resulted in preliminary findings and a tax assessment and additional uncertain tax position reserve for open tax years have been recorded in the amount of $0.2 million. We have tax years open in Germany beginning in fiscal 2015 and the Netherlands beginning in fiscal 2011.

On September 12, 2017, the Company received an income tax refund from the State of Illinois of approximately $2.0 million, which was inclusive of interest earned. The refund was a result of the conclusion of the Illinois amended return related to the sale of the RF, Wireless and Power Division in 2011. A net benefit of $1.5 million, which includes $0.5 million of professional fee costs incurred to pursue the refund, was recognized in the second quarter of fiscal 2018 in discontinued operations.

We have historically determined that certain undistributed earnings of our foreign subsidiaries, to the extent of cash available, will be repatriated to the U.S. Accordingly, we have provided a deferred tax liability totaling $5.7 million as of December 2, 2017, on foreign earnings of $39.5 million. As of December 2, 2017, approximately $6.4 million balance of cumulative positive earnings of some of our foreign subsidiaries are still considered permanently reinvested pursuant to ASC 740-30. Due to various tax attributes that are continuously changing, it is not practicable to determine what, if any, tax liability may exist if such earnings were to be repatriated.

~~As of December 2, 2017,~~March 3, 2018, our worldwide liability for uncertain tax positions related to continuing operations was $0.1 million, excluding interest and penalties, as compared to ~~$0.0~~no liability as of May 27, 2017. The change to the uncertain tax positions for the ~~second~~third quarter of fiscal 2018 was as a result of the preliminary German audit assessments and the related exposure for the open ~~years.~~years, which was reserved in the second quarter of fiscal 2018. We record penalties and interest relating to uncertain tax positions in the income tax expense line item within the unaudited consolidated statements of income (loss). It is not expected that there will be a change to unrecognized tax ~~benefits~~provision within the next 12 months.

The valuation allowance against the net deferred tax assets ~~has~~ increased to ~~$9.5~~$10.0 million as of ~~December 2, 2017 driven primarily by~~March 3, 2018. Changes during the first nine months relating to the Act include the impact from the deferred remeasurement, deemed earnings repatriation tax and changes to the permanent reinvestment assertion outside basis difference as a result of the Act. Additional impacts to the valuation allowance include an Illinois income tax rate increase and ~~the impact on the overall federal and Illinois deferred tax assets as well as~~ additional domestic federal and state net deferred tax assets generated during the first ~~two~~three quarters of fiscal year 2018 due to additional losses in the U.S. jurisdiction. The valuation allowance against the net deferred tax assets ~~that will more likely than not be realized~~ was $8.5 million as of May 27, 2017. A full valuation allowance on the U.S. and state deferred tax assets will be maintained until sufficient positive evidence related to sources of future taxable income exists to support a reversal of the valuation allowance. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are increased, or if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be given to subjective evidence such as our projections for growth.

We have authorized 17,000,000 shares of common stock, and 3,000,000 shares of Class B common stock. The Class B common stock has 10 votes per share and has transferability restrictions; however, Class B common stock may be converted into common stock on a share-for-share basis at any time. With respect to dividends and distributions, shares of common stock and Class B common stock rank equally and have the same rights, except that Class B common stock cash dividends are limited to 90% of the amount of Class A common stock cash dividends.

In accordance with ASC 260-10, Earnings Per Share (“ASC 260”), our Class B common stock is considered a participating security requiring the use of the two-class method for the computation of basic and diluted earnings per share. The two-class computation method for each period reflects the cash dividends paid per share for each class of stock, plus the amount of allocated undistributed earnings per share computed using the participation percentage which reflects the dividend rights of each class of stock. Basic and diluted earnings per share were computed using the two-class method as prescribed in ASC 260. The shares of Class B common stock are considered to be participating convertible securities since the shares of Class B common stock are convertible on a share-for-share basis into shares of common stock and may participate in dividends with common stock according to a predetermined formula which is 90% of the amount of Class A common stock cash dividends.

The earnings per share (“EPS”) presented in our unaudited consolidated statements of comprehensive income (loss) are based on the following amounts (in thousands, except per share amounts):

Note: Common stock options that were anti-dilutive and not included in diluted earnings per common share for the ~~second~~third quarter of fiscal 2017 was ~~893.~~853.

Note: Common stock options that were anti-dilutive and not included in diluted earnings per common share for the first ~~six~~nine months of fiscal 2017 was ~~893.~~853.

In accordance with ASC 280-10, Segment Reporting, we have identified three operating and reportable segments as follows:

Canvys provides customized display solutions serving the corporate enterprise, financial, healthcare, industrial, and medical original equipment manufacturers (“OEM”) markets.

The CEO evaluates performance and allocates resources primarily based on the gross profit of each segment.

Operating results by segment are summarized in the following table (in thousands):

	Three Months Ended				Six Months Ended				Three Months Ended				Nine Months Ended
	December 2,		November 26,		December 2,		November 26,		March 3,		February 25,		March 3,		February 25,
	2017		2016		2017		2016		2018		2017		2018		2017
PMT
Net Sales	$	30,063	$	25,229	$	59,187	$	50,610	$	31,869	$	24,763	$	91,056	$	75,373
Gross Profit		10,262		8,273		19,836		15,728		10,656		8,075		30,492		23,803
Canvys
Net Sales	$	6,707	$	5,439	$	12,472	$	10,059	$	7,585	$	4,824	$	20,057	$	14,883
Gross Profit		2,128		1,543		3,674		2,891		2,571		1,331		6,245		4,222
Healthcare
Net Sales	$	2,312	$	3,159	$	4,418	$	6,531	$	2,191	$	2,726	$	6,609	$	9,257
Gross Profit		984		1,148		2,012		2,585		840		1,286		2,852		3,871

Geographic net sales information is primarily grouped by customer destination into five areas: North America; Asia/Pacific; Europe; Latin America; and Other.

Net sales and gross profit by geographic region are summarized in the following table (in thousands):

	Three Months Ended						Six Months Ended						Three Months Ended						Nine Months Ended
	December 2,			November 26,			December 2,			November 26,			March 3,			February 25,			March 3,			February 25,
	2017			2016			2017			2016			2018			2017			2018			2017
Net Sales
North America	$	15,846		$	14,059		$	30,909		$	27,108		$	18,748		$	13,607		$	49,657		$	40,715
Asia/Pacific		7,457			6,621			14,467			14,276			6,635			5,916			21,102			20,192
Europe		13,615			11,204			26,115			21,468			14,197			10,950			40,312			32,418
Latin America		2,141			1,956			4,560			4,346			2,086			1,792			6,646			6,138
Other (1)		23			(13	)		26			2			(21	)		48			5			50
Total	$	39,082		$	33,827		$	76,077		$	67,200		$	41,645		$	32,313		$	117,722		$	99,513
Gross Profit
North America	$	6,186		$	4,947		$	11,792		$	9,832		$	6,955		$	5,258		$	18,747		$	15,090
Asia/Pacific		2,545			2,369			4,925			4,927			2,331			2,085			7,256			7,012
Europe		4,484			3,747			8,589			6,776			4,904			3,764			13,493			10,540
Latin America		854			777			1,818			1,694			820			643			2,638			2,337
Other (1)		(695	)		(876	)		(1,602	)		(2,025	)		(943	)		(1,058	)		(2,545	)		(3,083	)
Total	$	13,374		$	10,964		$	25,522		$	21,204		$	14,067		$	10,692		$	39,589		$	31,896

We sell our products to customers in diversified industries and perform periodic credit evaluations of our customers’ financial condition. Terms are generally on open account, payable net 30 days in North America, and vary throughout Asia/Pacific, Europe and Latin America. Estimates of credit losses are recorded in the financial statements based on monthly reviews of outstanding accounts.

On December 5, 2017, Steven H. Busch filed a Verified Stockholder Derivative Complaint against Edward J. Richardson, Paul Plante, Jacques Belin, James Benham, Kenneth Halverson, and the Company in the Delaware Court of Chancery, captioned Steven H. Busch v. Edward J. Richardson, et al., C.A. No. 2017-0868-AGB. The lawsuit alleges claims for breach of fiduciary duty by the Company’s directors and challenges the decision of a special committee of the Company’s Board to refuse Mr. Busch’s demand that the Company’s Board, among other things, rescind the Company’s May 2013 repurchase of stock from Mr. Richardson and May 2013 and October 2014 repurchases of Company stock from the Richardson Wildlife Foundation. The Company believes the lawsuit to be without merit and that a loss is not probable or estimable based on the information available at the time the financial statements were issued.

ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), defines fair value, establishes a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.

ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists; therefore requiring an entity to develop its own assumptions.

As of ~~December 2, 2017~~March 3, 2018 and May 27, 2017, we held investments that are required to be measured at fair value on a recurring basis. Our investments currently consist of time deposits and CDs, where face value is equal to fair value, and as of May 27, 2017, equity securities of publicly traded companies for which market prices are readily available.

Investments measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of ~~December 2, 2017~~March 3, 2018 and May 27, 2017, were as follows (in thousands):

	Level 1		Level 1
December 2, 2017
March 3, 2018
Time deposits/CDs	$	4,136	$	199
Equity securities		686		—
Total	$	4,822	$	199
May 27, 2017
Time deposits/CDs	$	8,226	$	8,226
Equity securities		622		622
Total	$	8,848	$	8,848

On June 15, 2015, the Company entered into a lease agreement for the IMES facility with LDL, LLC. The Executive Vice President of IMES, Lee A. McIntyre III (former owner of IMES), has an ownership interest in LDL, LLC. The lease agreement provides for monthly payments over five years with total future minimum lease payments of ~~$0.4~~$0.3 million. Rental expense related to this lease amounted to $0.1 million for the ~~six~~nine months ended ~~December 2, 2017~~March 3, 2018 and for the ~~six~~nine months ended ~~November 26, 2016.~~February 25, 2017. The Company shall be entitled to extend the term of the lease for a period of an additional five years by notifying the landlord in writing of its intention to do so within nine months of the expiration of the initial term.

On December 22, 2017, the Tax Cuts and Jobs Act (“TCJA”) enacted significant changes to many elements of the United States Federal Internal Revenue Code. Due to the recent enactment of the TCJA and expected further rulemaking and future regulatory guidance, a comprehensive estimate of the overall tax impact to the Company cannot be made at this time. However, the Company anticipates that in the third quarter of fiscal 2018, the TCJA will potentially result in a discrete tax impact related to revaluing our U.S. federal deferred tax assets and liabilities, a discrete tax impact associated with currently including incremental earnings from our non-U.S. entities in the U.S. federal income tax base and a change to the Company’s fiscal 2018 estimated annual tax rate due to the tax rate reduction. These changes will impact the Company’s fiscal 2018 third quarter deferred income tax assets and liabilities on the Consolidated Balance Sheet. Certain adjustments, but not all, will be offset by an adjustment to the valuation allowance. The impact on the Company’s cash flow from operations cannot be reasonably determined at this time.

Certain statements in this report may constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. The terms “may,” “should,” “could,” “anticipate,” “believe,” “continues,” “estimate,” “expect,” “intend,” “objective,” “plan,” “potential,” “project” and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. These statements are based on management’s current expectations, intentions or beliefs and are subject to a number of factors, assumptions and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Factors that could cause or contribute to such differences or that might otherwise impact the business include the risk factors set forth in Item 1A, of our Annual Report on Form 10-K filed on July 31, 2017. We undertake no obligation to update any such factor or to publicly announce the results of any revisions to any forward-looking statements contained herein whether as a result of new information, future events or otherwise.

In addition, while we do, from time to time, communicate with securities analysts, it is against our policy to disclose to them any material non-public information or other confidential commercial information. Accordingly, stockholders should not assume that we agree with any statement or report issued by any analyst irrespective of the content of the statement or report. Thus, to the extent that reports issued by securities analysts contain any projections, forecasts, or opinions, such reports are not our responsibility.

Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to assist the reader in better understanding our business, results of operations, financial condition, changes in financial condition, critical accounting policies and estimates and significant developments. MD&A is provided as a supplement to, and should be read in conjunction with, our consolidated financial statements and the accompanying notes appearing elsewhere in this filing. This section is organized as follows:

Canvys provides customized display solutions serving the corporate enterprise, financial, healthcare, industrial, and medical original equipment manufacturers (“OEM”) markets.

We currently have operations in the following geographic regions: North America, Asia/Pacific, Europe and Latin America.

Financial Summary – ~~Six~~Nine Months Ended ~~December 2, 2017~~March 3, 2018

Net sales by segment and percent change for the ~~second~~third quarter and first ~~six~~nine months of fiscal 2018 and 2017 were as follows (in thousands):

Net Sales	Three Months Ended				FY18 vs. FY17			Three Months Ended				FY18 vs. FY17
	December 2, 2017		November 26, 2016		% Change			March 3, 2018		February 25, 2017		% Change
PMT	$	30,063	$	25,229		19.2	%	$	31,869	$	24,763		28.7	%
Canvys		6,707		5,439		23.3	%		7,585		4,824		57.2	%
Healthcare		2,312		3,159		-26.8	%		2,191		2,726		-19.6	%
Total	$	39,082	$	33,827		15.5	%	$	41,645	$	32,313		28.9	%

	Six Months Ended				FY18 vs. FY17			Nine Months Ended				FY18 vs. FY17
	December 2, 2017		November 26, 2016		% Change			March 3, 2018		February 25, 2017		% Change
PMT	$	59,187	$	50,610		16.9	%	$	91,056	$	75,373		20.8	%
Canvys		12,472		10,059		24.0	%		20,057		14,883		34.8	%
Healthcare		4,418		6,531		-32.4	%		6,609		9,257		-28.6	%
Total	$	76,077	$	67,200		13.2	%	$	117,722	$	99,513		18.3	%

During the ~~second~~third quarter of fiscal 2018 consolidated net sales increased ~~15.5%~~28.9% compared to the ~~second~~third quarter of fiscal 2017. Sales for PMT increased ~~19.2%~~28.7%, sales for Canvys increased ~~23.3%~~57.2% and sales for Healthcare decreased 26.8%. The increase in PMT was due to sales of power grid tubes as well as specialty products manufactured in LaFox which are sold into the semiconductor capital equipment market and sales from new technology partners in power conversion and RF and microwave components. The increase for Canvys was primarily due to increased customer demand in our European market. The decrease in Richardson Healthcare was due to the sale of the PACS display business at the end of fiscal 2017 which was partially offset by higher sales of certified pre-owned CT tubes.

During the first six months of fiscal 2018 consolidated net sales increased 13.2% compared to the first six months of fiscal 2017. Sales for PMT increased 16.9%, sales for Canvys increased 24.0%, and sales for Healthcare decreased 32.4%19.6%. The increase in PMT was due to specialty products engineered and manufactured in LaFox which are sold to the semiconductor capital market and new technology partners in power conversion and RF and microwave components. The increase for Canvys was due to increased customer demand in both our North American and European markets. The decrease in Richardson Healthcare was primarily due to the sale of the PACS display business at the end of fiscal 2017, ~~which was~~ partially offset by higher sales of ~~refurbished~~ equipment and certified ~~pre-owned~~and refurbished CT tubes.

During the first nine months of fiscal 2018 consolidated net sales increased 18.3% compared to the first nine months of fiscal 2017. Sales for PMT increased 20.8%, sales for Canvys increased 34.8% and sales for Healthcare decreased 28.6%. The increase in PMT was due to specialty products engineered and manufactured in LaFox which are sold to the semiconductor capital market, new technology partners in power conversion and RF and microwave components, complemented by increased sales of power grid tubes. The increase for Canvys was due to increased customer demand in both our North American and European markets. The decrease in Richardson Healthcare was primarily due to the sale of the PACS display business at the end of fiscal 2017, partially offset by higher sales of equipment and certified and refurbished CT tubes.

Gross profit by segment and percent of net sales for the ~~second~~third quarter and first ~~six~~nine months of fiscal 2018 and 2017 were as follows (in thousands):

Gross Profit	Three Months Ended										Three Months Ended
	December 2, 2017		% of Net Sales			November 26, 2016		% of Net Sales			March 3, 2018		% of Net Sales			February 25, 2017		% of Net Sales
PMT	$	10,262		34.1	%	$	8,273		32.8	%	$	10,656		33.4	%	$	8,075		32.6	%
Canvys		2,128		31.7	%		1,543		28.4	%		2,571		33.9	%		1,331		27.6	%
Healthcare		984		42.6	%		1,148		36.3	%		840		38.3	%		1,286		47.2	%
Total	$	13,374		34.2	%	$	10,964		32.4	%	$	14,067		33.8	%	$	10,692		33.1	%

	Six Months Ended										Nine Months Ended
	December 2, 2017		% of Net Sales			November 26, 2016		% of Net Sales			March 3, 2018		% of Net Sales			February 25, 2017		% of Net Sales
PMT	$	19,836		33.5	%	$	15,728		31.1	%	$	30,492		33.5	%	$	23,803		31.6	%
Canvys		3,674		29.5	%		2,891		28.7	%		6,245		31.1	%		4,222		28.4	%
Healthcare		2,012		45.5	%		2,585		39.6	%		2,852		43.2	%		3,871		41.8	%
Total	$	25,522		33.5	%	$	21,204		31.6	%	$	39,589		33.6	%	$	31,896		32.1	%

Gross profit reflects the distribution and manufacturing product margin less manufacturing variances, inventory obsolescence charges, customer returns, scrap and cycle count adjustments, engineering costs ~~unabsorbed manufacturing labor and overhead,~~ and other provisions.

Consolidated gross profit increased to ~~$13.4~~$14.1 million during the ~~second~~third quarter of fiscal 2018, compared to ~~$11.0~~$10.7 million during the ~~second~~third quarter of fiscal 2017. Consolidated gross margin as a percentage of net sales increased to ~~34.2%~~33.8% during the ~~second~~third quarter of fiscal 2018, from ~~32.4%~~33.1% during the ~~second~~third quarter of fiscal 2017, primarily due to favorable product mix for PMT and favorable product mix and lower costs on selected products for ~~Canvys and the sale of the PACS display business, which generated lower margins in our Healthcare business.~~Canvys.

Consolidated gross profit increased to ~~$25.5~~$39.6 million during the first ~~six~~nine months of fiscal 2018, compared to ~~$21.2~~$31.9 million during the first ~~six~~nine months of fiscal 2017. Consolidated gross margin as a percentage of net sales increased to ~~33.5%~~33.6% during the first ~~six~~nine months of fiscal 2018, from ~~31.6%~~32.1% during the first ~~six~~nine months of fiscal 2017, primarily due to favorable product mix for PMT, favorable product mix and lower costs on selected products for Canvys and the sale of the PACS display business, which generated lower margins in our Healthcare business.

PMT net sales increased ~~19.2%~~28.7% to ~~$30.1~~$31.9 million during the ~~second~~third quarter of fiscal 2018, from ~~$25.2~~$24.8 million during the ~~second~~third quarter of fiscal 2017. The increase ~~included sales of power grid tubes as well as~~was due to specialty products engineered and manufactured in LaFox which are sold ~~primarily into~~to the semiconductor capital ~~equipment~~ market and ~~sales from~~ new technology partners in power conversion and RF and microwave components. Gross margin as a percentage of net sales increased to ~~34.1%~~33.4% during the ~~second~~third quarter of fiscal 2018, as compared to ~~32.8%~~32.6% during the ~~second~~third quarter of fiscal 2017, due to favorable product ~~mix and favorable manufacturing results from our LaFox production facility.~~mix.

PMT net sales increased ~~16.9%~~20.8% to ~~$59.2~~$91.1 million during the first ~~six~~nine months of fiscal 2018, from ~~$50.6~~$75.4 million during the first ~~six~~nine months of fiscal 2017. The increase included sales of specialty products engineered and manufactured in LaFox which are sold primarily into the semiconductor capital equipment market, ~~and~~ sales from new technology partners in power conversion and RF and microwave ~~components.~~components, complemented by increased sales of power grid tubes. Gross margin as a percentage of net sales increased to 33.5% during the first ~~six~~nine months of fiscal 2018, as compared to ~~31.1%~~31.6% during the ~~six~~nine months of fiscal 2017, due to favorable product ~~mix.~~mix and favorable manufacturing results from our LaFox production facility.

Canvys net sales increased ~~23.3%~~57.2% to ~~$6.7~~$7.6 million during the ~~second~~third quarter of fiscal 2018, from ~~$5.4~~$4.8 million during the ~~second~~third quarter of fiscal 2017 ~~primarily~~ due to increased customer demand in both our North American and European ~~market.~~markets. Gross margin as a percentage of net sales increased to ~~31.7%~~33.9% during the ~~second~~third quarter of fiscal 2018 as compared to ~~28.4%~~27.6% during the ~~second~~third quarter of fiscal 2017, due to favorable product mix and lower costs on selected products sold.

Canvys net sales increased ~~24.0%~~34.8% to ~~$12.5~~$20.1 million during the first ~~six~~nine months of fiscal 2018, from ~~$10.1~~$14.9 million during the first ~~six~~nine months of fiscal 2017 due to increased customer demand in both our North American and European markets. Gross margin as a percentage of net sales increased to ~~29.5%~~31.1% during the first ~~six~~nine months of fiscal 2018 as compared to ~~28.7%~~28.4% during the first ~~six~~nine months of fiscal 2017, due to favorable product mix and lower costs on selected products sold.

Healthcare net sales decreased ~~26.8%~~19.6% to ~~$2.3~~$2.2 million during the ~~second~~third quarter of fiscal 2018, from ~~$3.2~~$2.7 million during the ~~second~~third quarter of fiscal 2017 primarily due to the sale of the PACS display business at the end of fiscal 2017, partially offset by ~~an increase in the~~higher sales of equipment and certified ~~pre-owned~~and refurbished CT ~~Tubes.~~tubes. Gross margin as a percentage of net sales ~~increased~~decreased to ~~42.6%~~38.3% during the ~~second~~third quarter of fiscal 2018 as compared to ~~36.3%~~47.2% during the ~~second~~third quarter of fiscal 2017 due to ~~the sale of the PACS display business, which generated lower margins.~~an unfavorable product mix that favored equipment sales.

Healthcare net sales decreased ~~32.4%~~28.6% to ~~$4.4~~$6.6 million during the first ~~six~~nine months of fiscal 2018, from ~~$6.5~~$9.3 million during the first ~~six~~nine months of fiscal 2017 primarily due to the sale of the PACS display business at the end of fiscal 2017, partially offset by ~~an increase in the~~higher sales of equipment and certified ~~pre-owned~~and refurbished CT ~~Tubes and Equipment.~~tubes. Gross margin as a percentage of net sales increased to ~~45.5%~~43.2% during the first ~~six~~nine months of fiscal 2018 as compared to ~~39.6%~~41.8% during the first ~~six~~nine months of fiscal 2017 due to the sale of the PACS display business, which generated lower ~~margins.~~margins, offset partially by an unfavorable product mix that favored equipment sales.

Selling, general and administrative expenses ~~(“SG&A“) decreased~~increased to ~~$12.6~~$13.1 million during the ~~second~~third quarter of fiscal 2018 from ~~$13.4~~$12.0 million toin the ~~second~~third quarter of fiscal 2017. The ~~decrease~~increase was due to higher compensation and other expenses mostly related to the increase in net sales as well as higher research and development costs and other incremental expenses for Richardson Healthcare. Operating expenses as a percent of sales decreased to 31.4% in the third quarter of fiscal 2018 from 37.1% in the third quarter of fiscal 2017.

Selling, general and administrative expenses increased to $38.0 million during the first nine months of fiscal 2018 from $37.7 million during the first nine months of fiscal 2017. The increase was due to higher compensation and other expenses mostly related to the increase in net sales as well as higher research and development costs and other incremental expenses to support our growth strategies in Richardson Healthcare. The increase was partially offset by a charge of $1.3 million in the second quarter of fiscal 2017 for severance expense related to a reduction in workforce, partially offset by higher research and development expenses as well as increased investment costs to support our growth strategies in PMT and Healthcare. Operating expenses as a percent of sales decreased to 32.2% in the current quarter from 35.7% last year when excluding the severance expense from the second quarter of fiscal 2017.

Selling, general and administrative expenses (“SG&A“) decreased to $24.9 million during the first six months of fiscal 2018 from $25.7 million during the first six months of fiscal 2017. The decrease was due to a charge of $1.3 million in the second quarter of fiscal 2017 for severance expense related to a reduction in workforce, partially offset by higher research and development expenses as well as increased investment costs to support our growth strategies in PMT and Healthcare.workforce.

Other income/expense was less than $0.1 million ~~of expense~~ during the ~~second~~third quarter of fiscal 2018, compared to ~~income~~expense of ~~$0.2~~$0.1 million during the ~~second~~third quarter of fiscal 2017. Other income/expense during the ~~second~~third quarter of fiscal 2018 included ~~$0.1~~$0.2 million of foreign exchange ~~losses.~~losses and $0.2 million of investment/interest income. Other ~~income~~expense during the ~~second~~third quarter of fiscal 2017 included $0.2 million of foreign exchange ~~gains.~~losses and $0.1 million of investment/interest income. Our foreign exchange gains and losses are primarily due to the translation of U.S. dollars held in non-U.S. entities. We currently do not utilize derivative instruments to manage our exposure to foreign currency.

Other income/expense was $0.1 million of expense during the first ~~six~~nine months of fiscal 2018, compared to expense of ~~$0.1~~$0.2 million during the first ~~six~~nine months of fiscal 2017. Other expense during the first ~~six~~nine months of fiscal 2018 included ~~$0.3~~$0.5 million of foreign exchange losses partially offset by ~~$0.2~~$0.4 million of investment/interest income. Other expense during the first ~~six~~nine months of fiscal 2017 included ~~$0.1~~$0.3 million of foreign exchange ~~losses.~~losses and $0.1 million of investment/interest income. Our foreign exchange gains and losses are primarily due to the translation of U.S. dollars held in non-U.S. entities. We currently do not utilize derivative instruments to manage our exposure to foreign currency.

The 21% corporate income tax rate was effective January 1, 2018. Based on the Company’s June 2, 2018 fiscal year end, the U.S. statutory income tax rate for fiscal 2018 will be approximately 29.2%.

Net income ~~including income from discontinued operations of $1.5 million,~~ during the ~~second~~third quarter of fiscal 2018 was ~~$1.7~~$0.5 million or ~~$0.13~~$0.04 per diluted common share and ~~$0.12~~$0.04 per Class B diluted common share, as compared to net loss of ~~$2.5~~$1.4 million during the ~~second~~third quarter of fiscal 2017, or ($~~0.20)~~0.11) per diluted common share and ($~~0.18)~~0.10) per Class B diluted common share.

Net income, including income from discontinued operations of $1.5 million, during the first ~~six~~nine months of fiscal 2018 was ~~$1.6~~$2.1 million, or ~~$0.12~~$0.17 per diluted common share and ~~$0.11~~$0.15 per Class B diluted common share, as compared to net loss of ~~$5.4~~$6.8 million during the first ~~six~~nine months of fiscal 2017, or ($~~0.43)~~0.54) per diluted common share and ($~~0.38)~~0.48) per Class B diluted common share.

Our operations and cash needs have been primarily financed through income from operations and cash on hand.

Cash and cash equivalents were ~~$54.5~~$59.9 million at ~~December 2, 2017.~~March 3, 2018. Investments included CDs and time deposits classified as short-term investments of ~~$4.1 million and long-term investments in equity securities of $0.7~~$0.2 million. Cash and investments at ~~December 2, 2017,~~March 3, 2018, consisted of ~~$8.8~~$9.4 million in North America, ~~$17.6~~$19.4 million in Europe, ~~$1.5~~$1.1 million in Latin America, and ~~$31.4~~$30.2 million in Asia/Pacific.

Cash and cash equivalents were $55.4 million at May 27, 2017. Investments included CD’s and time deposits, classified as short-term investments were $6.4 million and long-term investments were $2.4 million including equity securities of $0.6 million. Cash and investments at May 27, 2017, consisted of $16.3 million in North America, $15.5 million in Europe, $1.5 million in Latin America and $30.9 million in Asia/Pacific. During the first quarter of fiscal 2017, we completed a cash repatriation of $11.3 million, which included a return of capital and dividend from our Chinese entity to our U.S. parent company.

We believe that the existing sources of liquidity, including current cash, will provide sufficient resources to meet known capital requirements and working capital needs through the next twelve months.

The cash used in operating activities primarily resulted from adjustments for non-cash items and changes in our operating assets and liabilities.

Operating activities used ~~$2.3~~$0.3 million of cash during the first ~~six~~nine months of fiscal 2018. We had net income of ~~$1.6~~$2.1 million during the first ~~six~~nine months of fiscal 2018, which included non-cash stock-based compensation expense of ~~$0.3~~$0.4 million associated with the issuance of stock option and restricted stock awards and depreciation and amortization expense of ~~$1.5~~$2.2 million associated with our property and equipment as well as amortization of our intangible assets. Changes in our operating assets and liabilities during the first ~~six~~nine months of fiscal 2018, net of foreign currency exchange gains and losses, included an increase in inventories of ~~$4.6~~$5.2 million, a decrease of ~~$1.0~~$0.4 million in accounts payable and an increase in prepaid expenses and other assets of $0.6 million, partially offset by an increase in accrued liabilities of $1.3 million. The inventory increase was due to the ongoing growth of our RF and power technologies business, increase in raw material and work in process supporting the semiconductor capital equipment market and growth in supplying replacement systems and parts to the Healthcare market. The decrease in our accounts payable was due to timing of payments for some of our larger vendors for both inventory and services.

Operating activities used ~~$1.9~~$3.2 million of cash during the first ~~six~~nine months of fiscal 2017. We had net loss of ~~$5.4~~$6.8 million during the first ~~six~~nine months of fiscal 2017, which included non-cash stock-based compensation expense of ~~$0.3~~$0.4 million associated with the issuance of stock option awards, deferred income tax credit adjustment of ~~$0.3~~$0.2 million, and depreciation and amortization expense of ~~$1.3~~$2.0 million associated with our property and equipment as well as amortization of our intangible assets. Changes in our operating assets and liabilities during the first ~~six~~nine months of fiscal 2017, net of foreign currency exchange gains and losses, included an increase of $1.0 million in prepaid expenses, ~~and~~ a decrease of ~~$3.2~~$2.4 million in accounts payable and a decrease in other accrued liabilities of $0.3 million, partially offset by decreases in receivables of ~~$3.9~~$3.2 million and inventories of ~~$1.6 million, and an increase in other accrued liabilities of $0.9~~$1.9 million. The decrease in receivables of ~~$3.9~~$3.2 million was primarily due to the collection of a large receivable during the first quarter of fiscal 2017 that was invoiced during the fourth quarter of fiscal 2016. The inventory decrease was due to decreases in selected electron tubes. The decrease in our accounts payable was due to timing of payments for some of our larger vendors and also the result of shorter payment terms for our Richardson Healthcare vendors.

The cash flow from investing activities has consisted primarily of purchases and maturities of investments and capital expenditures.

Cash provided by investing activities of ~~$1.8~~$4.9 million during the first ~~six~~nine months of fiscal 2018 included proceeds from the maturities of investments of ~~$8.2~~$12.1 million, partially offset by $3.9 million from purchases of investments and ~~$2.7~~$4.2 million in capital expenditures. Capital expenditures relates primarily to our Healthcare growth initiatives, a new roof for part of our warehouse and capital used for our ~~new~~ IT system.

Cash used by investing activities of ~~$1.9~~$2.6 million during the first ~~six~~nine months of fiscal 2017, included proceeds from the maturities of investments of $3.6 million, offset by $2.1 million from purchases of investments and ~~$3.3~~$4.1 million in capital expenditures. Capital expenditures relates primarily to our Healthcare growth ~~initiatives~~initiative and capital used for our new IT system.

Our purchases and proceeds from investments consist of time deposits and CDs. Purchasing of future investments may vary from period to period due to interest and foreign currency exchange rates.

Cash used in financing activities of ~~$1.5~~$2.2 million during the first ~~six~~nine months of fiscal 2018 resulted from cash used to pay dividends.

Cash used in financing activities of ~~$1.5~~$2.2 million during the first ~~six~~nine months of fiscal 2017 resulted from cash used to pay dividends.

Dividend payments for the first ~~six~~nine months of fiscal 2018 were approximately ~~$1.5~~$2.3 million. All future payments of dividends are at the discretion of the Board of Directors. Dividend payments will depend on earnings, capital requirements, operating conditions, and such other factors that the Board may deem relevant.

We are exposed to many different market risks with the various industries we serve. The primary financial risk we are exposed to is foreign currency exchange, as certain operations, assets and liabilities of ours are denominated in foreign currencies. We manage these risks through normal operating and financing activities.

The interpretation and analysis of these disclosures should not be considered in isolation since such variances in exchange rates would likely influence other economic factors. Such factors, which are not readily quantifiable, would likely also affect our operations. Additional disclosure regarding various market risks are set forth in Part I, Item 1A, “Risk Factors“ of our Annual Report on Form 10-K for the year ended May 27, 2017, filed July 31, 2017.

Management of the Company, with the participation of the Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of ~~December 2, 2017.~~March 3, 2018.

Disclosure controls and procedures are intended to provide reasonable assurance that information required to be disclosed in the Company’s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to management, including the Company’s Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Based on this evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of the end of the period covered by this report.

There were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during the ~~second~~third quarter of fiscal 2018 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended May 27, 2017, filed July 31, 2017.

On ~~January 10,~~April 11, 2018, we issued a press release reporting results for our ~~second~~third quarter ended ~~December 2, 2017,~~March 3, 2018, and the declaration of a cash dividend. A copy of the press release is furnished as Exhibit 99.1 to this Form 10-Q and incorporated by reference herein.

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Delaware	36-2096643
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

40W267 Keslinger Road, P.O. Box 393 LaFox, Illinois 60147-0393
(Address of principal executive offices)

Large Accelerated Filer	☐	Accelerated Filer	☒
Non-Accelerated Filer	☐ (Do not check if a smaller reporting company)	Smaller Reporting Company	☐
Emerging Growth Company	☐


		Page

Part I.	Financial Information

Item 1.	Financial Statements	32
	Consolidated Balance Sheets	32
	Unaudited Consolidated Statements of Comprehensive Income (Loss)	43
	Unaudited Consolidated Statements of Cash Flows	54
	Unaudited Consolidated Statement of Stockholders’ Equity	65
	Notes to Unaudited Consolidated Financial Statements	76
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	24
Item 4.	Controls and Procedures	24

Part II.	Other Information

Item 1.	Legal Proceedings	25
Item 1A.	Risk Factors	25
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	25
Item 5.	Other Information	25
Item 6.	Exhibits	25
Signatures		26
Exhibit Index		27


	Unaudited		Audited
	December 2, 2017		May 27, 2017
Assets
Current assets:
Cash and cash equivalents	$	54,453	$	55,327
Accounts receivable, less allowance of $373 and $398, respectively		21,016		20,782
Inventories, net		48,059		42,749
Prepaid expenses and other assets		3,729		3,070
Investments - current		4,136		6,429
Total current assets		131,393		128,357
Non-current assets:
Property, plant and equipment, net		17,275		15,813
Goodwill		6,332		6,332
Intangible assets, net		3,231		3,441
Non-current deferred income taxes		1,069		1,102
Investments - non-current		686		2,419
Total non-current assets		28,593		29,107
Total assets	$	159,986	$	157,464
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	15,224	$	15,933
Accrued liabilities		8,645		8,311
Total current liabilities		23,869		24,244
Non-current liabilities:
Non-current deferred income tax liabilities		158		158
Other non-current liabilities		903		735
Total non-current liabilities		1,061		893
Total liabilities		24,930		25,137
Stockholders’ equity
Common stock, $0.05 par value; issued and outstanding 10,790 shares at December 2, 2017 and 10,712 shares at May 27, 2017		535		535
Class B common stock, convertible, $0.05 par value; issued and outstanding 2,137 shares at December 2, 2017 and at May 27, 2017		107		107
Preferred stock, $1.00 par value, no shares issued		—		—
Additional paid-in-capital		59,745		59,436
Common stock in treasury, at cost, no shares at December 2, 2017 and at May 27, 2017		—		—
Retained earnings		69,368		69,333
Accumulated other comprehensive income		5,301		2,916
Total stockholders’ equity		135,056		132,327
Total liabilities and stockholders’ equity	$	159,986	$	157,464


	Unaudited		Audited
	March 3, 2018		May 27, 2017
Assets
Current assets:
Cash and cash equivalents	$	59,882	$	55,327
Accounts receivable, less allowance of $362 and $398, respectively		21,893		20,782
Inventories, net		49,129		42,749
Prepaid expenses and other assets		3,746		3,070
Investments - current		199		6,429
Total current assets		134,849		128,357
Non-current assets:
Property, plant and equipment, net		17,991		15,813
Goodwill		6,332		6,332
Intangible assets, net		3,125		3,441
Non-current deferred income taxes		1,061		1,102
Investments - non-current		—		2,419
Total non-current assets		28,509		29,107
Total assets	$	163,358	$	157,464
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	15,846	$	15,933
Accrued liabilities		9,867		8,311
Total current liabilities		25,713		24,244
Non-current liabilities:
Non-current deferred income tax liabilities		236		158
Other non-current liabilities		947		735
Total non-current liabilities		1,183		893
Total liabilities		26,896		25,137
Stockholders’ equity
Common stock, $0.05 par value; issued and outstanding 10,796 shares at March 3, 2018 and 10,712 shares at May 27, 2017		540		535
Class B common stock, convertible, $0.05 par value; issued and outstanding 2,137 shares at March 3, 2018 and May 27, 2017		107		107
Preferred stock, $1.00 par value, no shares issued		—		—
Additional paid-in-capital		59,900		59,436
Common stock in treasury, at cost, no shares at March 3, 2018 and May 27, 2017		—		—
Retained earnings		69,132		69,333
Accumulated other comprehensive income		6,783		2,916
Total stockholders’ equity		136,462		132,327
Total liabilities and stockholders’ equity	$	163,358	$	157,464

	●	Business Overview – a brief synopsis of our Company for the periods ended ~~December 2, 2017~~March 3, 2018 and ~~November 26, 2016.~~February 25, 2017.

	●	Results of Operations – an analysis and comparison of our consolidated results of operations for the three and ~~six~~nine month periods ended ~~December 2,~~March 3, 2018 and February 25, 2017, ~~and November 26, 2016,~~ as reflected in our consolidated statements of comprehensive income (loss).

	●	Liquidity, Financial Position and Capital Resources – a discussion of our primary sources and uses of cash for the three and ~~six~~nine month periods ended ~~December 2,~~March 3, 2018, and February 25, 2017, ~~and November 26, 2016,~~ and a discussion of changes in our financial position.


	●	Net sales for the ~~second~~third quarter of fiscal 2018 were ~~$39.1~~$41.6 million, an increase of ~~15.5%~~28.9%, compared to net sales of ~~$33.8~~$32.3 million during the ~~second~~third quarter of fiscal 2017.

	●	Gross margin increased to ~~34.2%~~33.8% during the ~~second~~third quarter of fiscal 2018, compared to ~~32.4%~~33.1% during the ~~second~~third quarter of fiscal 2017.

	●	Selling, general and administrative expenses were ~~$12.6~~$13.1 million, or ~~32.2%~~31.4% of net sales, for the ~~second~~third quarter of fiscal 2018, compared to ~~$13.4~~$12.0 million, or ~~39.5%~~37.1% of net sales, for the ~~second~~third quarter of fiscal 2017.

	●	Operating income during the ~~second~~third quarter of fiscal 2018 was ~~$0.8~~$1.0 million, compared to an operating loss of ~~$2.4~~$1.3 million in the ~~second~~third quarter of fiscal 2017.

	●	~~Income from continuing operations~~Net income during the ~~second~~third quarter of fiscal 2018 was ~~$0.2 million, compared to loss from continuing operations of $2.5 million in the second quarter of fiscal 2017.~~

	●	~~Income from discontinued operations during the second quarter of fiscal 2018 was $1.5 million. There was no income (loss) from discontinued operations during the second quarter of fiscal 2017.~~

	●	~~Net income during the second quarter of fiscal 2018 was $1.7~~$0.5 million, compared to net loss of ~~$2.5~~$1.4 million during the ~~second~~third quarter of fiscal 2017.

	●	Net sales for the first ~~six~~nine months of fiscal 2018 were ~~$76.1~~$117.7 million, an increase of ~~13.2%~~18.3%, compared to net sales of ~~$67.2~~$99.5 million during the first ~~six~~nine months of fiscal 2017.

	●	Gross margin increased to ~~33.5%~~33.6% during the first ~~six~~nine months of fiscal 2018, compared to ~~31.6%~~32.1% during the first ~~six~~nine months of fiscal 2017.

	●	Selling, general and administrative expenses were ~~$24.9~~$38.0 million, or ~~32.8%~~32.3% of net sales, for the first ~~six~~nine months of fiscal 2018, compared to ~~$25.7~~$37.7 million, or ~~38.2%~~37.9% of net sales, for the first ~~six~~nine months of fiscal 2017.

	●	Operating income during the first ~~six~~nine months of fiscal 2018 was ~~$0.8~~$1.8 million, compared to an operating loss of ~~$4.5~~$5.8 million in the first ~~six~~nine months of fiscal 2017.

	●	Income from continuing operations during the first ~~six~~nine months of fiscal 2018 was ~~$0.1~~$0.6 million, compared to loss from continuing operations of ~~$5.4~~$6.8 million in the first ~~six~~nine months of fiscal 2017.

	●	Income from discontinued operations during the first ~~six~~nine months of fiscal 2018 was $1.5 million. There was no income (loss) from discontinued operations during the first ~~six~~nine months of fiscal 2017.

	●	Net income during the first ~~six~~nine months of fiscal 2018 was ~~$1.6~~$2.1 million, compared to net loss of ~~$5.4~~$6.8 million during the first ~~six~~nine months of fiscal 2017.

ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

ITEM 5.	OTHER INFORMATION

	RICHARDSON ELECTRONICS, LTD.

Date: ~~January 11,~~April 12, 2018	By:	/s/	Robert J. Ben
			Robert J. Ben Chief Financial Officer and Chief Accounting Officer (on behalf of the Registrant and as Principal Financial Officer)

		EXHIBITS

Exhibit Number		Description
3.1		Amended and Restated Certificate of Incorporation of the Company, incorporated by reference to Annex III of the Proxy Statement dated August 22, 2014.

3.2		Amended and Restated By-Laws of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 15, 2017).

31.1		Certification of Edward J. Richardson pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Robert J. Ben pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32		Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

99.1		Press release, dated ~~January 10,~~April 11, 2018.

101		The following financial information from our Quarterly Report on Form 10-Q for the ~~second~~third quarter of fiscal 2018, filed with the SEC on ~~January 11,~~April 12, 2018, formatted in Extensible Business Reporting Language (XBRL): (i) the Consolidated Balance Sheets, (ii) the Unaudited Consolidated Statements of Comprehensive Income (Loss), (iii) the Unaudited Consolidated Statements of Cash Flows, (iv) the Unaudited Consolidated Statement of Stockholder’s Equity and (v) Notes to Unaudited Consolidated Financial Statements.